MedTrace Logo

Molecular Targets for the Treatment of Histiocytosis

NCT04437381 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2023-09-06

No results posted yet for this study

Summary

The primary objective: to develop technical and operating procedures for detection mutations of histiocytosis during clinical practice of no-specialized molecular platforms, for diagnosis and follow-up of the disease.

The secondary objectives: to describe therapeutic target mutations in histiocytosis patients, and to develop the cellular tests to evaluate in vitro the sensibility of these mutations drive to inhibitors.

Conditions

  • Histiocytosis

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Direction de l'Hospitalisation et de l'Organisation des Soins

    collaborator UNKNOWN

  • Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University

    collaborator UNKNOWN

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jean-François EMILE, MD, PhD · Department of Pathology, Ambroise Paré hospital, APHP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-22
Primary Completion
2025-04-30
Completion
2025-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04437381 on ClinicalTrials.gov